Cresco Labs (CL) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
25 Dec, 2025Executive summary
FY 2024 revenue was $724.3 million, a 6% year-over-year decline, but with a more profitable and sustainable mix and strong brand and retail performance offsetting price compression.
Adjusted EBITDA grew 15% to $200 million (28% margin), and operating cash flow reached a record $132 million, up 126% year-over-year.
Net loss for FY 2024 was $60 million, including $66 million in one-time, non-cash charges related to updated 280E tax position.
Focused on operational excellence, cash generation, and strategic capital deployment, including expansion in core and new markets such as Kentucky.
Maintained #1 market share in Illinois, Pennsylvania, and Massachusetts, with share growth in Ohio and Florida.
Financial highlights
Adjusted gross profit margin increased to 52% in FY 2024 from 49% in FY 2023; adjusted gross profit dollars held flat year-over-year despite lower revenue.
Adjusted SG&A reduced by $29 million in 2024, with Q4 SG&A at $54 million, down 1% year-over-year; adjusted SG&A margin was 29% for FY 2024.
Q4 revenue was $176 million; Q4 adjusted EBITDA was $42 million (24% of revenue); Q4 operating cash flow was $29 million.
Free cash flow for FY 2024 was $114 million, up from $5.8 million in FY 2023.
Net loss for FY 2024 was $(60.5) million, a significant improvement from $(179.9) million in FY 2023.
Outlook and guidance
Near-term margin pressure expected in Q1 2025 as production scales up in Illinois and Pennsylvania; SG&A to remain relatively flat in Q1, with modest increases as expansion continues in Ohio, Florida, Pennsylvania, and Kentucky.
Growth initiatives underway, but not expected to materially impact Q1; focus remains on sustainable long-term growth and maximizing core markets.
Kentucky market expected to contribute meaningfully from 2026 onward; industry analysts project Kentucky market to exceed $228 million by 2028.
Long-term gross margin target of 50% remains unchanged.
Anticipated annual cash tax benefit of ~$70 million from revised tax strategy starting 2025.
Latest events from Cresco Labs
- Q4 2025 revenue was $162M with margin gains, but net loss was driven by impairment charges.CL
Q4 20255 Mar 2026 - All resolutions, including director elections and incentive plan changes, were approved.CL
EGM 20243 Feb 2026 - Q2 saw margin and cash flow gains, with growth expected as adult-use markets expand.CL
Q2 20242 Feb 2026 - All resolutions passed, directors elected, and shareholders invited to Q&A after formal business.CL
EGM 202519 Jan 2026 - Q3 2024 saw record cash flow, margin gains, and top market share amid strategic growth moves.CL
Q3 202415 Jan 2026 - Vertically integrated U.S. cannabis operator launches multi-security shelf offering amid regulatory risks.CL
Registration Filing29 Nov 2025 - Q1 2025 delivered $166M revenue, strong cash flow, and market leadership despite margin pressure.CL
Q1 202525 Nov 2025 - Q2 2025 revenue hit $164M, 25% EBITDA margin, and debt refinancing supports future growth.CL
Q2 202523 Nov 2025 - Q3 2025 revenue hit $165M, with strong market share, improved cash flow, and debt refinancing.CL
Q3 202513 Nov 2025